---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-084515"
form_type: "8-K"
ticker: "XOMA"
cik: "0000791908"
company_name: "XOMA Royalty Corp"
filed_at: "2023-03-30T23:59:59+00:00"
generated_at: "2026-06-17T09:53:00.843249+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# XOMA acquires IXINITY royalty and milestone payments from Aptevo for $9.6M

## Summary
- XOMA (US) LLC paid $9.6M to Aptevo for 100% of deferred payments on IXINITY net sales, plus partial milestone payments.
- IXINITY is a hemophilia B treatment marketed by Medexus; purchased receivables stem from a 2020 Aptevo-Medexus sale agreement.
- Additional $50k payment to Aptevo if XOMA receives >$500k of Q1 2023 deferred payments from IXINITY.
- Agreement includes customary covenants, representations, and indemnification provisions.

## SEC filing metadata
- accession: 0001193125-23-084515
- form_type: 8-K
- ticker: XOMA
- cik: 0000791908
- company_name: XOMA Royalty Corp
- filed_at: 2023-03-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/791908/000119312523084515/0001193125-23-084515-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/791908/000119312523084515/d477933d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-084515
- JSON: https://secwatch.observer/filing/0001193125-23-084515.json
- Plain text: https://secwatch.observer/filing/0001193125-23-084515.txt

## Key facts
- Material Agreements
  XOMA Royalty Corp entered into Payment Interest Purchase Agreement with Aptevo Therapeutics Inc. valued at $9.6 million (effective 2023-03-29).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: Aptevo Therapeutics Inc.
  - Value: $9.6 million
  - Effective: 2023-03-29
  source text: On March 29, 2023, XOMA (US) LLC (“XOMA”), a wholly-owned subsidiary of XOMA Corporation (the “Company”), entered into a Payment Interest Purchase Agreement (the “Agreement”) with Aptevo Therapeutics Inc., a Delaware corporation (“Aptevo”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/791908/000119312523084515/0001193125-23-084515-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.